Eagle's Eye View: Your Weekly CV Update From ACC.org

Dr. Eagle dives into the effectiveness of pulsed-field ablation for pulmonary vein isolation, revealing its impressive durability statistics. He also explores the genetic nuances of dilated cardiomyopathy, highlighting a significant incidence in genotype-positive relatives. In addition, there's a fascinating comparison of reintervention rates between TAVR and SAVR for severe aortic stenosis, showcasing some unexpected insights into when and why reinterventions occur. Tune in for a blend of cutting-edge research and practical insights!

In this week's View, Dr. Eagle looks at a scientific statement from the American Heart Association on the diagnosis and management of cardiac sarcoidosis. He then examines the temporal trends and clinical implications of ischemic stroke in women with atrial fibrillation. Finally, Dr. Eagle shares some thoughts on transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR). Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at a systematic review and meta-analysis of antibiotic prophylaxis and infective endocarditis incidence following invasive dental procedures. He then examines the issue of serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban. Finally, Dr. Eagle shares some thoughts on low-dose colchicine for secondary prevention in atherosclerosis. Subscribe to Eagle's Eye View

A special edition introducing ACC24 with insights into practice-changing updates, new drugs, and device therapies. Top experts debate and discuss results of trials, share visual abstracts, and show how it fits into practice. Transformation of care begins at ACC.24.

Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from Day 3, Monday, April 7 at the American College of Cardiology Scientific Sessions 2024 in Atlanta. Trials on Monday include TARGET BP I (0:39), DEDICATE-DZHK6 (3:07), and FULL REVASC (6:31). For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #ACC24. Subscribe to Eagle's Eye View

Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from Day 2, Sunday, April 6 at the American College of Cardiology Scientific Sessions 2024 in Atlanta. Trials on Sunday include REDUCE-AMI (0:35), DanGer-Shock (3:28), ULTIMATE-DAPT (6:17) and TACT2 (10:04). For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #ACC24. Subscribe to Eagle's Eye View

Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from Day 1, Saturday, April 5 at the American College of Cardiology Scientific Sessions 2024 in Atlanta. Trials on Saturday include AEGIS II (0:45), VICTORION-INITIATE (2:36), RELIEVE-HF (5:27) and Step-HFpEF Dm (8:42). For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #ACC24. Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at the timing of complete multivessel revascularization in patients presenting with non-ST-Elevation Acute Coronary Syndrome, then examines the accuracy of wearable heart rate monitors during exercise in sinus rhythm and atrial fibrillation. Finally, Dr. Eagle shares some thoughts on a multinational observation study on sports-related sudden cardiac death. Subscribe to Eagle's Eye View

In this special edition of Eagle's Eye View, Dr. Eagle highlights the latest science and innovation being presented at ACC.24 in Atlanta, Georgia from April 6-8. He gives us valuable insights into practice-changing updates in care. The topics include late-breaking clinical trials and science focusing on new drugs and device therapies. Tune into ACC.org's coverage of ACC.24 to hear from the top experts as they debate, discuss the results of the trials, share visual abstracts and find out how it all fits into your practice. The transformation of care begins at ACC.24. Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aortic stenosis. Finally, Dr. Eagle shares some thoughts on current concepts regarding transcatheter treatment of tricuspid valve regurgitation. Subscribe to Eagle's Eye View